Literature DB >> 2910432

Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors.

K R Geisinger1, T E Kute, M J Pettenati, C E Welander, Y Dennard, L A Collins, M E Berens.   

Abstract

The potential significant therapeutic and prognostic roles for the sex steroid receptors in ovarian cancer are recognized. The authors present in detail the biochemical, morphologic, cytogenetic, and growth characteristics of an ovarian carcinoma cell line, BG-1, which has functional estrogen and progesterone receptors (23 and 300 fmol/mg protein, respectively) in clinically significant levels. In particular, BG-1 has a DNA index of 1.14, a stable karyotype with specific translocations, and produces and secretes CA 125 into the media.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2910432     DOI： 10.1002/1097-0142(19890115)63:2<280::aid-cncr2820630213>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  28 in total

1.  Error-promoting DNA synthesis in ovarian cancer cells.

Authors:  Heqiao Dai; Robert J Hickey; Jianying Liu; Robert M Bigsby; Carita Lanner; Linda H Malkas
Journal:  Gynecol Oncol       Date:  2013-07-12       Impact factor: 5.482

2.  MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Authors:  Karina E Hew; Philip C Miller; Dorraya El-Ashry; Jun Sun; Alexandra H Besser; Tan A Ince; Mengnan Gu; Zhi Wei; Gao Zhang; Patricia Brafford; Wei Gao; Yiling Lu; Gordon B Mills; Joyce M Slingerland; Fiona Simpkins
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

3.  In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Hightower; R Ramos; D Donato; M Penalver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Negative regulation of estrogen signaling by ERβ and RIP140 in ovarian cancer cells.

Authors:  Aurélie Docquier; Aurélie Garcia; Julien Savatier; Abdel Boulahtouf; Sandrine Bonnet; Virginie Bellet; Muriel Busson; Emmanuel Margeat; Stéphan Jalaguier; Cathy Royer; Patrick Balaguer; Vincent Cavaillès
Journal:  Mol Endocrinol       Date:  2013-07-24

5.  Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Authors:  Fiona Simpkins; Pedro Hevia-Paez; Jun Sun; Wendy Ullmer; Candace A Gilbert; Thiago da Silva; Ali Pedram; Ellis R Levin; Isildinha M Reis; Brian Rabinovich; Diana Azzam; Xiang-Xi Xu; Tan A Ince; Ji-Yeon Yang; Roel G W Verhaak; Yiling Lu; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

6.  BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.

Authors:  L Zheng; L A Annab; C A Afshari; W H Lee; T G Boyer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

7.  MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Authors:  Lingtao Jin; Jaemoo Chun; Chaoyun Pan; Dan Li; Ruiting Lin; Gina N Alesi; Xu Wang; Hee-Bum Kang; Lina Song; Dongsheng Wang; Guojing Zhang; Jun Fan; Titus J Boggon; Lu Zhou; Jeanne Kowalski; Cheng-Kui Qu; Conor E Steuer; Georgia Z Chen; Nabil F Saba; Lawrence H Boise; Taofeek K Owonikoko; Fadlo R Khuri; Kelly R Magliocca; Dong M Shin; Sagar Lonial; Sumin Kang
Journal:  Cancer Cell       Date:  2018-07-19       Impact factor: 31.743

8.  Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.

Authors:  Andrea Schröpfer; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Sonja Feix; Jelena Anacker
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

9.  Conditionally immortal ovarian cell lines for investigating the influence of ovarian stroma on the estrogen sensitivity and tumorigenicity of ovarian surface epithelial cells.

Authors:  Feng Jiang; Beatriz O Saunders; Edward Haller; Sandra Livingston; Santo V Nicosia; Wenlong Bai
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

10.  Relationship of cell survival, drug dose, and drug uptake after 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine treatment.

Authors:  K Fujiwara; L W Daniel; E J Modest; C A Wallen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.